$PFE News Stock market live blog: SP 500 record, Twitter

New Post Public Reply Private Reply Replies (0) Message Board

Nov 21, 2013 at 8:11 PM

$PFE News

Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Pfizer profit falls, adjusts full-year views 7:24 a.m. Oct. 29, 2013 - MarketWatch.com
Pfizer net falls, adjusts full-year earnings range 7:18 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 revenue down 2% to $12.64 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 profit falls 19% to $2.59 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 EPS falls to $0.39; adj. EPS up to $0.58 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Cat's warning sign, a Michael Kors pop and the surf pounds Portugal 6:11 a.m. Oct. 29, 2013 - blogs.marketwatch.com
Apple, LinkedIn, Pfizer, Michael Kors: hot stocks 5:30 a.m. Oct. 29, 2013 - Ben Eisen
Apple angst, India rate hike: The next 24 hours in markets 6:17 p.m. Oct. 28, 2013 - blogs.marketwatch.com

Pfizer Gets FDA Nod for Xalkori Lung Cancer Drug and 2 Other Dow Movers to Watch 1:53 p.m. Today - Wall St. Cheat Sheet
Data on Amgen's Pipeline Candidates - Analyst Blog 11:50 a.m. Today - Zacks.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Today - Zacks.com
Athersys Narrows Loss, Shares Rise - Analyst Blog 9:00 a.m. Today - Zacks.com
Daiichi Sankyo's Factor Xa Inhibitor Edoxaban Clears Phase III Hurdle - A Major Threat To Xarelto And Eliquis 8:35 a.m. Today - Seeking Alpha
Roche's Kadcyla Approved in the EU - Analyst Blog 5:35 p.m. Nov. 20, 2013 - Zacks.com
Will Recent News Hurt Johnson & Johnson? 5:08 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet
Amazon.com Cloud Push Seen Creating 'Losers' In IT 4:21 p.m. Nov. 20, 2013 - Investors Business Daily
Early Warning Signs of a Dividend Cut 10:39 a.m. Nov. 20, 2013 - GuruFocus.com
Daiichi Sankyo's edoxaban holds its own in clinical testing 10:26 a.m. Nov. 20, 2013 - Seeking Alpha
EU Clears Roche Cancer Drug 5:44 a.m. Nov. 20, 2013 - WSJ.com
More Boards Recruit Ex-CEOs 9:47 p.m. Nov. 19, 2013 - WSJ.com
QIAGEN, Eli Lilly Expand Partnership - Analyst Blog 6:58 p.m. Nov. 19, 2013 - Zacks.com
New Tricks in Animal Health 6:05 p.m. Nov. 19, 2013 - WSJ.com
Nokia Shareholders Nod to Microsoft Deal and 2 Other Hot Stocks to Watch 12:38 p.m. Nov. 19, 2013 - Wall St. Cheat Sheet
Bullying: Deal With It 12:16 p.m. Nov. 19, 2013 - FOXBusiness
The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years 11:03 a.m. Nov. 19, 2013 - 247WallSt.com
Salesforce's Q3 Loss Widens - Analyst Blog 9:30 a.m. Nov. 19, 2013 - Zacks.com
Pfizer Inc's Buy Recommendation Affirmed 9:00 a.m. Nov. 19, 2013 - TheStreet.com
4 ETFs to Turbocharge Your Returns 3:22 a.m. Nov. 19, 2013 - InvestorPlace.com

Pfizer's XALKORI(R) Granted Regular FDA Approval 11:00 a.m. Today - BusinessWire
Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma 8:00 a.m. Today - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Today - PR Newswire
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer 7:00 a.m. Today - GlobeNewswire
Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align Technology 8:00 a.m. Nov. 19, 2013 - PR Newswire
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ(R) (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis 4:47 p.m. Nov. 18, 2013 - BusinessWire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014 8:30 a.m. Nov. 14, 2013 - BusinessWire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Athersys Recognized Among Fastest Growing Companies in North America on Deloitte's 2013 Technology Fast 500(TM) 2:00 p.m. Nov. 13, 2013 - GlobeNewswire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients 8:00 a.m. Nov. 8, 2013 - BusinessWire
The Global Revolution in Biotechnology and the Impact of Regenerative Medicine 9:53 a.m. Nov. 7, 2013 - ACCESSWIRE
GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting 9:11 a.m. Nov. 7, 2013 - BusinessWire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
2013 mHealth Summit Launches First Pharma and Life Sciences Roundtable 2:31 p.m. Nov. 6, 2013 - PR Newswire
Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern 12:32 p.m. Nov. 5, 2013 - BusinessWire
Pfizer Receives FDA Approval for a Prior Approval Supplement for EMBEDA(R) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII 5:14 p.m. Nov. 4, 2013 - BusinessWire
Therapeutic Area Partnerships Feature Pharma Leaders Who Unveil How to Pick Drug Targets, Partners, and Deal Models Most Likely to Succeed 9:00 a.m. Nov. 4, 2013 - Marketwire
Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application - Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK 9:00 a.m. Nov. 1, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...